Somatic <i>CALR</i> Mutations in Myeloproliferative Neoplasms with Nonmutated <i>JAK2</i>Jyoti Nangalia, Anthony R. Green, Elli Papaemmanuil et al.|New England Journal of Medicine|2013Cited by 1.7k
A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosisAlessandro M. Vannucchi, H. Kantarjian, Jean‐Jacques Kiladjian et al.|Haematologica|2015Cited by 252
A Large Proportion of Patients With a Diagnosis of Essential Thrombocythemia Do Not Have a Clonal Disorder and May Be at Lower Risk of Thrombotic ComplicationsClaire Harrison, David C. Linch, Rosemary E. Gale et al.|Blood|1999Cited by 213
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 studySrđan Verstovšek, Aaron T. Gerds, Alessandro M. Vannucchi et al.|The Lancet|2023Cited by 181
The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studiesVikas Gupta, Srđan Verstovšek, Claire Harrison et al.|Haematologica|2016Cited by 85